What is the projected market valuation of the Anti-Fungal Drugs Market by 2035?

The projected market valuation of the Anti-Fungal Drugs Market is 28.95 USD Billion by 2035. Read More

What was the market valuation of the Anti-Fungal Drugs Market in 2024?

The market valuation of the Anti-Fungal Drugs Market was 18.51 USD Billion in 2024. Read More

What is the expected CAGR for the Anti-Fungal Drugs Market during the forecast period 2025 - 2035?

The expected CAGR for the Anti-Fungal Drugs Market during the forecast period 2025 - 2035 is 4.15%. Read More

Which drug class is projected to have the highest valuation in the Anti-Fungal Drugs Market by 2035?

The Azoles drug class is projected to reach a valuation of 9.0 USD Billion by 2035. Read More

What are the projected valuations for the Oral formulation type in the Anti-Fungal Drugs Market by 2035?

The Oral formulation type is projected to reach a valuation of 10.5 USD Billion by 2035. Read More

How does the market for Therapeutic Treatment compare to Prophylactic Treatment in 2035?

By 2035, the market for Therapeutic Treatment is projected to be valued at 23.35 USD Billion, significantly higher than the 5.6 USD Billion for Prophylactic Treatment. Read More

What is the projected market size for Adult patients in the Anti-Fungal Drugs Market by 2035?

The projected market size for Adult patients in the Anti-Fungal Drugs Market is 15.75 USD Billion by 2035. Read More

Which company is among the key players in the Anti-Fungal Drugs Market?

Pfizer is one of the key players in the Anti-Fungal Drugs Market. Read More

What is the projected valuation for Skin Infections in the Anti-Fungal Drugs Market by 2035?

The projected valuation for Skin Infections in the Anti-Fungal Drugs Market is 5.5 USD Billion by 2035. Read More

What is the expected growth trend for the Echinocandins drug class by 2035?

The Echinocandins drug class is expected to grow to a valuation of 6.0 USD Billion by 2035. Read More

Anti-Fungal Drugs Market

ID: MRFR/HC/30154-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Anti-Fungal Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Nicotinamides), By Formulation Type (Injectable, Oral, Topical, Intravaginal), By Treatment Type (Prophylactic Treatment, Therapeutic Treatment), By Patient Type (Pediatric, Adult, Geriatric), By Conditions Treated (Skin Infections, Systemic Infections, Oral Candidiasis, Nail Infections) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Anti-Fungal Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.15%

2024 Market Size$ 18.51 Billion

2025 Market Size$ 19.27 Billion

2035 Market Size$ 28.95 Billion

Key Players

Pfizer

Bristol-Myers Squibb

Merck & Co.

Gilead Sciences

Novartis

Astellas Pharma

Trends

Rising Incidence of Fungal Infections
Advancements in Drug Development
Shift Towards Personalized Medicine

Opportunities

Regulatory Support for Drug Approvals
Rising Awareness of Fungal Infections
Increase in Immunocompromised Populations

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Drug Class (USD Billion)
  1. 4.1.1 Azoles
  2. 4.1.2 Echinocandins
  3. 4.1.3 Polyenes
  4. 4.1.4 Allylamines
  5. 4.1.5 Nicotinamides
2. 4.2 Healthcare, BY Formulation Type (USD Billion)
  1. 4.2.1 Injectable
  2. 4.2.2 Oral
  3. 4.2.3 Topical
  4. 4.2.4 Intravaginal
3. 4.3 Healthcare, BY Treatment Type (USD Billion)
  1. 4.3.1 Prophylactic Treatment
  2. 4.3.2 Therapeutic Treatment
4. 4.4 Healthcare, BY Patient Type (USD Billion)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5. 4.5 Healthcare, BY Conditions Treated (USD Billion)
  1. 4.5.1 Skin Infections
  2. 4.5.2 Systemic Infections
  3. 4.5.3 Oral Candidiasis
  4. 4.5.4 Nail Infections
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Astellas Pharma (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bayer (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GlaxoSmithKline (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE
5. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE
6. 6.6 US MARKET ANALYSIS BY PATIENT TYPE
7. 6.7 US MARKET ANALYSIS BY CONDITIONS TREATED
8. 6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
9. 6.9 CANADA MARKET ANALYSIS BY FORMULATION TYPE
10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT TYPE
11. 6.11 CANADA MARKET ANALYSIS BY PATIENT TYPE
12. 6.12 CANADA MARKET ANALYSIS BY CONDITIONS TREATED
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY DRUG CLASS
15. 6.15 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
17. 6.17 GERMANY MARKET ANALYSIS BY PATIENT TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY CONDITIONS TREATED
19. 6.19 UK MARKET ANALYSIS BY DRUG CLASS
20. 6.20 UK MARKET ANALYSIS BY FORMULATION TYPE
21. 6.21 UK MARKET ANALYSIS BY TREATMENT TYPE
22. 6.22 UK MARKET ANALYSIS BY PATIENT TYPE
23. 6.23 UK MARKET ANALYSIS BY CONDITIONS TREATED
24. 6.24 FRANCE MARKET ANALYSIS BY DRUG CLASS
25. 6.25 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
27. 6.27 FRANCE MARKET ANALYSIS BY PATIENT TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY CONDITIONS TREATED
29. 6.29 RUSSIA MARKET ANALYSIS BY DRUG CLASS
30. 6.30 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
32. 6.32 RUSSIA MARKET ANALYSIS BY PATIENT TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY CONDITIONS TREATED
34. 6.34 ITALY MARKET ANALYSIS BY DRUG CLASS
35. 6.35 ITALY MARKET ANALYSIS BY FORMULATION TYPE
36. 6.36 ITALY MARKET ANALYSIS BY TREATMENT TYPE
37. 6.37 ITALY MARKET ANALYSIS BY PATIENT TYPE
38. 6.38 ITALY MARKET ANALYSIS BY CONDITIONS TREATED
39. 6.39 SPAIN MARKET ANALYSIS BY DRUG CLASS
40. 6.40 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
42. 6.42 SPAIN MARKET ANALYSIS BY PATIENT TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY CONDITIONS TREATED
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY CONDITIONS TREATED
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY DRUG CLASS
51. 6.51 CHINA MARKET ANALYSIS BY FORMULATION TYPE
52. 6.52 CHINA MARKET ANALYSIS BY TREATMENT TYPE
53. 6.53 CHINA MARKET ANALYSIS BY PATIENT TYPE
54. 6.54 CHINA MARKET ANALYSIS BY CONDITIONS TREATED
55. 6.55 INDIA MARKET ANALYSIS BY DRUG CLASS
56. 6.56 INDIA MARKET ANALYSIS BY FORMULATION TYPE
57. 6.57 INDIA MARKET ANALYSIS BY TREATMENT TYPE
58. 6.58 INDIA MARKET ANALYSIS BY PATIENT TYPE
59. 6.59 INDIA MARKET ANALYSIS BY CONDITIONS TREATED
60. 6.60 JAPAN MARKET ANALYSIS BY DRUG CLASS
61. 6.61 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
63. 6.63 JAPAN MARKET ANALYSIS BY PATIENT TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY CONDITIONS TREATED
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY CONDITIONS TREATED
70. 6.70 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
71. 6.71 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
73. 6.73 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY CONDITIONS TREATED
75. 6.75 THAILAND MARKET ANALYSIS BY DRUG CLASS
76. 6.76 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
78. 6.78 THAILAND MARKET ANALYSIS BY PATIENT TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY CONDITIONS TREATED
80. 6.80 INDONESIA MARKET ANALYSIS BY DRUG CLASS
81. 6.81 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
83. 6.83 INDONESIA MARKET ANALYSIS BY PATIENT TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY CONDITIONS TREATED
85. 6.85 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
86. 6.86 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
88. 6.88 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY CONDITIONS TREATED
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY DRUG CLASS
92. 6.92 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
94. 6.94 BRAZIL MARKET ANALYSIS BY PATIENT TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY CONDITIONS TREATED
96. 6.96 MEXICO MARKET ANALYSIS BY DRUG CLASS
97. 6.97 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
99. 6.99 MEXICO MARKET ANALYSIS BY PATIENT TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY CONDITIONS TREATED
101. 6.101 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
102. 6.102 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
104. 6.104 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY CONDITIONS TREATED
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY CONDITIONS TREATED
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY CONDITIONS TREATED
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY CONDITIONS TREATED
122. 6.122 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
123. 6.123 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
125. 6.125 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY CONDITIONS TREATED
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY CONDITIONS TREATED, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY CONDITIONS TREATED, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.2.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.3.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.3.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.4.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.4.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.5.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.5.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.6.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.6.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.7.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.7.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.8.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.8.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.9.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.9.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.10.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.10.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.11.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.11.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.12.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.12.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.13.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.13.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.14.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.14.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.15.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.15.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.16.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.16.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.17.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.17.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.18.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.18.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.19.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.19.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.20.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.20.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.21.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.21.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.22.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.22.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.23.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.23.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.24.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.24.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.25.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.25.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.26.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.26.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.27.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.27.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.28.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.28.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.29.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.29.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.30.2 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  5. 7.30.5 BY CONDITIONS TREATED, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Anti-Fungal Drugs Market Segmentation

Anti-Fungal Drugs Market By Drug Class (USD Billion, 2025-2035)

Azoles
Echinocandins
Polyenes
Allylamines
Nicotinamides

Anti-Fungal Drugs Market By Formulation Type (USD Billion, 2025-2035)

Injectable
Oral
Topical
Intravaginal

Anti-Fungal Drugs Market By Treatment Type (USD Billion, 2025-2035)

Prophylactic Treatment
Therapeutic Treatment

Anti-Fungal Drugs Market By Patient Type (USD Billion, 2025-2035)

Pediatric
Adult
Geriatric

Anti-Fungal Drugs Market By Conditions Treated (USD Billion, 2025-2035)

Skin Infections
Systemic Infections
Oral Candidiasis
Nail Infections

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”